Valuation, from the filing
| Public float | $9.10B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-12-31 |
|---|---|---|
| Float per share | $58.03 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / revenue | 7.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 4.3× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2026-06-30 — the year that filing covered.
Valuation over time
155.3× earnings today, against a median of 57.2× across 9 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2024-12-31 | $11.40B | 155.3× | |
| 2023-12-31 | $12.10B | 72.0× | |
| 2022-12-31 | $13.00B | 45.6× | |
| 2021-12-31 | $20.30B | 74.6× | |
| 2020-12-31 | $12.40B | 88.3× | |
| 2019-12-31 | $8.40B | 36.6× | |
| 2018-12-31 | $5.50B | 57.2× | |
| 2017-12-31 | $3.40B | 27.0× | |
| 2016-12-31 | $3.80B | 49.9× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| SBC / revenue | 3.4% | 6th | |
| FCF margin | 21.7% | 91th | |
| Operating margin | 20.7% | 88th | |
| Long-term debt / equity | 0.09x | 19th | |
| Effective tax rate | 24.4% | 76th | |
| CapEx / revenue | 2.4% | 37th | |
| Revenue YoY growth | -0.4% | 43th | |
| Gross margin | 65.8% | 46th | |
| Current ratio | 4.55x | 49th |
BIO-TECHNE Corp (TECH) reported revenue of $1.22B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIO-TECHNE Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $1.22B |
| Cost of revenue | $415.97M |
| Gross profit | $799.07M |
| Operating income | $251.89M |
| Net income | Unavailable |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $240.68M |
| Income tax expense | $58.82M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $452.42M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $264.71M |
| Total assets | $2.59B |
| Current assets | $744.40M |
| Total liabilities | Unavailable |
| Current liabilities | $163.70M |
| Total equity incl. NCI | $2.11B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $195.74M |
| Accounts receivable | $216.58M |
| Goodwill | $975.36M |
| Long-term debt | $200.00M |
| Accounts payable | $26.70M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $292.07M |
| Capital expenditures | $28.85M |
| Investing cash flow | -$18.19M |
| Financing cash flow | -$169.11M |
| Net change in cash | $102.53M |
| Stock-based compensation | $41.36M |
| Common dividends paid | $49.92M |
| Common share repurchases | $41.68M |
| Depreciation & amortization | $97.36M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $263.22M |
| Gross margin | 65.8% |
| Operating margin | 20.7% |
| FCF margin | 21.7% |
| SBC / revenue | 3.4% |
| Current ratio | 4.55x |
| Revenue YoY growth | -0.4% |
| Net margin | Unavailable |
| R&D / revenue | Unavailable |
| CapEx / revenue | 2.4% |
| Long-term debt / equity | 0.09x |
| Effective tax rate | 24.4% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TECH in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.